Emerging therapies for Down Syndrome, including AEF0217, ACI-24.060, and others, are anticipated to drive growth in the Down Syndrome market in the coming years.
DelveInsight has released a new report titled “Down Syndrome – Market Insights, Epidemiology, and Market Forecast-2034,” offering a comprehensive analysis of Down Syndrome, historical and projected epidemiology, and market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Discover about the Down Syndrome market report
Some of the key facts of the Down Syndrome Market Report:
-
In 2023, the Down Syndrome market in the United States was valued at approximately USD 241 million. Down Syndrome is a genetic disorder caused by a cell division error called “nondisjunction,” which results in a full or partial extra copy of chromosome 21. This additional genetic material affects development, giving rise to the physical and intellectual traits associated with the condition.
-
In the same year, the U.S. had nearly 220,000 prevalent cases of Down Syndrome, with a higher occurrence in females than males. The main types include Trisomy 21, Robertsonian translocation, and Mosaicism, with Trisomy 21 accounting for the majority of cases across the 7MM in 2023.
-
In March 2023, the U.S. FDA approved the expansion of Inspire® therapy for pediatric Down Syndrome patients aged 13–18 with moderate to severe obstructive sleep apnea (OSA). This approval permits the use of the Inspire Upper Airway Stimulation (UAS) system in adolescents with an apnea-hypopnea index (AHI) between 10 and 50 who cannot tolerate or benefit from CPAP therapy. The device is implanted near the collarbone and delivers mild stimulation to maintain an open airway during sleep.
-
There is no single standard treatment for Down Syndrome; care is tailored to each individual’s physical and intellectual needs, strengths, and limitations. Supportive care can be provided at home and in community settings.
-
In February 2021, the European Commission funded the ICOD project with EUR 6 million to support the clinical development of AEF0217 for cognitive deficits associated with Down Syndrome.
-
Key companies working on Down Syndrome therapies include AC Immune, Annovis Bio, Alzheon, OPKO Health, and Aelis Farma. Emerging treatments, such as AEF0217 and ACI-24.060, are expected to significantly advance the Down Syndrome treatment landscape.
-
According to the Global Down Syndrome Foundation, rare forms like translocation and mosaic Down Syndrome account for less than 6% of cases, where either not all chromosomes are triplicated or only some cells carry the extra chromosome. In 2023, the 0–18 age group represented the largest proportion of individuals living with Down Syndrome in the U.S.
Down Syndrome Overview
Down Syndrome is a genetic condition caused by a cell division error called “nondisjunction,” which results in an extra full or partial copy of chromosome 21. This additional genetic material disrupts normal development, giving rise to the characteristic physical and cognitive traits of the disorder. The condition manifests in three primary forms: Trisomy 21, Translocation Down Syndrome, and Mosaic Down Syndrome. Trisomy 21 is the most prevalent, with every cell carrying an extra chromosome 21, accounting for over 90% of cases. Each type presents distinct features and varying degrees of severity, leading to a broad spectrum of symptoms among affected individuals.
Down Syndrome Market Outlook
Down Syndrome (DS) is the most prevalent genetic cause of intellectual disability, caused by an extra copy of chromosome 21. Affected individuals exhibit a wide range of symptoms impacting multiple body systems, with considerable variation from case to case. Diagnosis is typically confirmed through karyotyping in newborns suspected of having DS, and genetic counseling is advised for families.
While there is no single cure for DS, various supportive therapies help individuals achieve their full potential. These include physical therapy to enhance motor skills, occupational therapy for daily living activities, speech therapy for communication, special education programs, behavioral counseling for coexisting conditions, participation in social activities, and regular medical check-ups to manage related health issues.
Additionally, several novel therapies, such as AEF0217 and ACI-24.060, are currently in early to mid-stage clinical trials, aiming to develop potential treatments for Down Syndrome.
Discover how the Down Syndrome market is rising in the coming years @ https://www.delveinsight.com/sample-request/down-syndrome-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Down Syndrome Emerging Drugs
-
AEF0217: Aelis Farma
Scope of the Down Syndrome Market Report
-
Study Period: 2020-2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Down Syndrome Companies: AC Immune, Annovis Bio, Alzheon, OPKO Health, Inc., Aelis Farma, and others
-
Key Down Syndrome Therapies: AEF0217, ACI-24.060, and others
-
Down Syndrome Therapeutic Assessment: Down Syndrome current marketed and Down Syndrome emerging therapies
-
Down Syndrome Market Dynamics: Down Syndrome market drivers and Down Syndrome market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Down Syndrome Unmet Needs, KOL’s views, Analyst’s views, Down Syndrome Market Access and Reimbursement
To know what’s more in our Down Syndrome report, visit https://www.delveinsight.com/report-store/down-syndrome-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Key benefits of the Down Syndrome Market Report:
-
Down Syndrome market report covers a descriptive overview and comprehensive insight of the Down Syndrome Epidemiology and Down Syndrome market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
-
The Down Syndrome market report provides insights into the current and emerging therapies.
-
The Down Syndrome market report provides a global historical and forecasted market covering drug outreach in 7MM.
-
The Down Syndrome market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Down Syndrome market.
Got queries? Click here to know more about the Down Syndrome market Landscape
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Down Syndrome Patient Share (%) Overview at a Glance
5. Down Syndrome Market Overview at a Glance
6. Down Syndrome Disease Background and Overview
7. Down Syndrome Epidemiology and Patient Population
8. Country-Specific Patient Population of Down Syndrome
9. Down Syndrome Current Treatment and Medical Practices
10. Unmet Needs
11. Down Syndrome Emerging Therapies
12. Down Syndrome Market Outlook
13. Country-Wise Down Syndrome Market Analysis (2020–2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Down Syndrome Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Click here to read more about Down Syndrome Market Outlook 2034
Related Reports:
Down Syndrome Pipeline Insights, DelveInsight
“Down Syndrome Pipeline Insight, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Down Syndrome market. A detailed picture of the Down Syndrome pipeline landscape is provided, which includes the disease overview and Down Syndrome treatment guidelines.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/